Comparison of pathological outcomes of neoadjuvant chemotherapy before surgery versus radical hysterectomy alone in stage IB3 and IIA2 cervical cancer

As an alternative treatment strategy, the efficacy of neoadjuvant chemotherapy (NAC) for patients with stage IB3 and IIA2 cervical carcinoma remains uncertain. To address this limitation, evaluates pathological outcomes locally advanced cancer (LACC) treated NAC before surgery compared those who underwent radical hysterectomy (RH) alone. A total 592 were eligible study. They divided into a group (NAC surgery, n = 259) RH (radical alone, 333). Propensity score matching (PSM) was used to eliminate confounding intergroup factors, leading 233 cases being finally included in two groups. Patients received 1–3 cycles nedaplatin plus paclitaxel/docetaxel/irinotecan regimens, followed by 3–5 weeks post-NAC. after diagnosis cancer. Intermediate-risk factors (i.e., lymphovascular space invasion deep stromal infiltration) high-risk lymph node metastasis, positive parametria surgical margin) recurrence LACC between groups PSM. The results showed no significant difference PSM (p > 0.05). In regard intermediate-risk observed inter-group analysis (lymphovascular invasion, p 0.028; infiltration, 0.011). After PSM, only infiltration remained significant, decreased incidence 0.004). conclusion, had minimal impact on group. However, we did observe decrease one-third invasion. These may be relevant decision-making process postoperative radiotherapy.